Press Releases
Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
November 16, 2019
Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows promise as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD), a condition that disproportionately afflicts women PHILADELPHIA (November 16, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS), a late-stage biopharmaceutical company focused on developing treatments for select cardiovascular diseases, along with researchers from Cedars-Sinai (Los Angeles), Mayo Clinic (Rochester, Minn.) and The Christ Hospital (Cincinnati),…
Read MoreCaladrius Biosciences Reports 2019 Third Quarter and Nine Month Financial Results and Provides Corporate Update
November 6, 2019
Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (November 6, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces financial results for the three and nine months ended September 30, 2019. “I am pleased with our third quarter performance as we continued to advance our ongoing CD34+ technology-based clinical programs for which…
Read MoreCaladrius Biosciences to Participate at Upcoming November Conferences
October 31, 2019
BASKING RIDGE, N.J. (October 31, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the Company will participate in the following conferences in November: LSX Inv€$tival Showcase in Partnership with Jefferies Date & Time: Tuesday, November 19, 2019 at 11:15 (GMT) Presenter: David J. Mazzo, Ph.D., President and Chief Executive Officer of…
Read MoreCaladrius Biosciences to Host 2019 Third Quarter Financial Results and Business Update Conference Call on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time
October 30, 2019
BASKING RIDGE, N.J. (October 30, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces that the Company will release financial results for the three and nine months ended September 30, 2019 after close of the U.S. financial markets on Wednesday, November 6, 2019. Caladrius’ management will host a conference call for the investment community beginning at…
Read MoreCaladrius Biosciences to Participate at the Upcoming October Conferences
October 1, 2019
BASKING RIDGE, N.J. (October 1, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will participate in the following conferences in October: 2019 Cell & Gene Meeting on the Mesa Date: Wednesday, October 2, 2019 Venue: Park Hyatt Aviara Resort in Carlsbad, CA Dawson James…
Read MoreCaladrius Biosciences to Participate at the Upcoming September Conferences
September 5, 2019
BASKING RIDGE, N.J. (September 5, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that management will participate in the following conferences in September: 21st Annual Global Investment Conference, Sponsored by H.C. Wainwright Date & Time: Tuesday, September 10, 2019 at 12:05 p.m. (EDT) Presenter: David J. Mazzo, Ph.D. Venue: …
Read MoreCaladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update
August 8, 2019
Confirmatory Phase 3 Study Protocol Finalized for CLBS14 in No-Option Refractory Disabling Angina Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. (August 8, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces financial results for the three and six months ended June 30, 2019 and provides highlights of progress within the development…
Read MoreCaladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina
August 7, 2019
BASKING RIDGE, NJ, AND MEMPHIS, TENN. (August 7, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, and Cognate BioServices, Inc. (“Cognate”), a leading contract development and manufacturing organization in the global cellular therapies industry, announced today that they have entered into a manufacturing agreement for the production of CLBS14, Caladrius’ CD34+ cell therapy. Under the terms of…
Read MoreCaladrius Biosciences to Host 2019 Second Quarter Financial Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. Eastern Time
August 1, 2019
BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announces that the Company will release financial results for the six months ended June 30, 2019 after close of the U.S. financial markets on Thursday, August 8, 2019. Caladrius’ management will host a conference call for the investment community beginning at 4:30 p.m. ET on Thursday,…
Read MoreCaladrius Biosciences Receives Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia
July 15, 2019
BASKING RIDGE, N.J. (July 15, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the European Medicines Agency (“EMA”) has granted Advanced Therapy Medicinal Product (“ATMP”) classification to the Company’s CD34+ cell therapy product, CLBS12, for the treatment of critical limb ischemia (“CLI”). Advanced therapy medicinal products are defined as medical treatments that are based…
Read MoreCaladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction
June 4, 2019
Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction Topline results expected by the end of 2019 BASKING RIDGE, N.J. (June 4, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today the completion of enrollment and dosing in the Phase 2 ESCaPE-CMD study for CLBS16 (formerly known as CLBS14-CMD) in patients with…
Read MoreCaladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update
May 9, 2019
All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively CLBS14-NORDA phase 3 program targeted to begin enrollment in late 2019 Cash on hand projected to support existing programs through 2Q2020 Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in…
Read MoreCaladrius Biosciences to Participate at the Upcoming May Conferences
May 7, 2019
BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announced today that management will participate in the following conferences in May: 16th International Symposium on Cardiovascular Regeneration and Repair Title: The Microcirculation: Center of the Cardiovascular Repair Universe Date…
Read MoreCaladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time
May 2, 2019
BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announces that the Company will release financial results for the three months ended March 31, 2019 after close of the U.S. financial markets on Thursday, May 9, 2019. Caladrius’ management…
Read MoreCaladrius Biosciences to Participate in Upcoming Conferences
April 3, 2019
BASKING RIDGE, N.J. – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announced today that David Mazzo, Ph.D., President and Chief Executive Officer of Caladrius Biosciences, will present a corporate overview at the following upcoming conferences: 26th Annual Future Leaders…
Read MoreCaladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
March 14, 2019
BASKING RIDGE, N.J. (March 14, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announces financial results for the three and twelve months ended December 31, 2018. “2018 was an exciting and productive year for Caladrius, featuring a number of significant…
Read MoreCaladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million
March 14, 2019
BASKING RIDGE, N.J. (March 14, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products focusing on select cardiovascular indications that have the potential to restore the health of people with chronic illnesses, announces that it has entered into a purchase agreement (“Purchase Agreement”) and a registration rights agreement with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which the Company has…
Read MoreCaladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time
March 13, 2019
BASKING RIDGE, N.J. (March 13, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announces that the Company will release financial results for the three and twelve months ended December 31, 2018 after close of the U.S. financial markets on Thursday,…
Read MoreCaladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day
March 11, 2019
BASKING RIDGE, N.J. (March 11, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announced today that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present at the Alliance for Regenerative Medicine (ARM) 7th Annual Cell…
Read MoreCaladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes
February 13, 2019
BASKING RIDGE, N.J. (February 13, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple development programs targeting select cardiovascular indications and autoimmune disease, today announced top-line results from The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2a clinical trial of 110 subjects to evaluate the safety and efficacy of the Company’s CLBS03 as a treatment for recent-onset type 1 diabetes (“T1D”) in adolescents. The…
Read More